11 Analysts Have This to Say About Regeneron Pharmaceuticals
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter: Bullish Somewhat Bullish Indifferent…
Sanofi/Regeneron’s Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that Dupixent&nb
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 5 years by 7.81% on an annualized basis…
9 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
How Is The Market Feeling About Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals’s (NYSE:REGN) short percent of float has fallen 4.67% since its last report. The company recently reported…
Regeneron Commits $34M Over Five Years To Continue To Sponsor The Regeneron International Science And Engineering Fair
Regeneron has sponsored ISEF - the world's largest high school science and engineering competition, and a program of Society for Science (Society) - since 2019 Each year, over 175,000 students participate in the
Where Regeneron Pharmaceuticals Stands With Analysts
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology
Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind – Analyst Review
Thursday, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported better-than-
Regeneron’s Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate